mRNA Therapeutics Market is expected to grow to USD 48.65 billion by 2032 at a CAGR of 17.04 %
The mRNA therapeutics market gained much attention due to the nature of the field in discussing chronic diseases and the advantages of DNA vaccines. Higher production efficiency and distribution capabilities along with safety profiles have enhanced the acceptance and popularity of mRNA vaccines. The U.S. provided reliable clinical results and used authorization urgently, late. FDA Approvals for COVID-19 mRNA vaccines, which showed a high efficacy of 94.1% in preventing symptomatic cases. The expansion of clinical trials across the globe and the growing use of stem cell therapy also drive the industry in line with market growth.